Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group Ltd. reported a 10% decrease in total revenue to RMB 949.7 million for the first half of 2024, with a significant 66.4% increase in medical aesthetics product sales being overshadowed by a 29.4% decline in their generic medicine business. Despite the overall revenue drop, innovative medicines showed an 85% revenue increase due to the launch of a new drug, Anaprazole Sodium. The company also saw a decline in R&D expenses by 33.5% and a 25.4% reduction in operating profit during the same period.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
